Skip to main content

Table 2 Summary of response rate (RR) and disease control (DCR) between Del-19 and L858R

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

 

RR (%)

p-value

DCR (%)

p-value

All patients (n = 78)

39.7

 

85.9

 

EGFR mutation status

 Del-19

36.1

0.54

80.6

0.21

 L858R

42.9

 

90.5

 
  1. Del-19 19 deletion; L858R Leu858Arg, EGFR epidermal growth factor receptor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us